(Date:10/8/2008)...n & Laser Center is well established as a tech...w York City. The facility is living up to its repu... skin resurfacing treatments to receive FDA approv..., New York, NY (PRWEB) Oct...atment industry is in the midst of an unprecedente...
(Date:10/7/2008)...elated Questions for Tonight,s,Presidential Debate...D, the leading source of,health information, today...ndidates, proposed health care policies, located a...candidates, stance on health insurance, medical an...c health issues., The in-depth coverage is just o...
(Date:10/7/2008)...Newswire-USNewswire/ -- IPRO, one of the,nation,s ...ations, has,created a Limited Liability Company (L...t oversight and consulting contracts with managed ...l (http://www.logiqual.com ), is now,officially i...w.newscom.com/cgi-bin/prnh/20081007/DC37283LOGO-a ...
(Date:10/7/2008)...-USNewswire/ -- As the presidential,candidates com...ate, Jean,Berg, a nursing assistant and member of ...waiting to ask John McCain why he wants to tax hea...o afford coverage., Berg has been a nursing assis...are., "It,s the single biggest economic factor in...
Breaking Medicine News(10 mins):Health News:Upscale New York City Skin Care Center Juva Offering FDA Approved Fraxel re:fine System 2Health News:WebMD Highlights Presidential Candidates' Views on Health Care 2Health News:IPRO Spins Off Managed Care Review Affiliate 2Health News:SEIU Member Will Be in Town Hall Audience, Ready to Ask John McCain Why He Won't Provide Affordable Healthcare for All 2(Date:10/7/2008)... FORT COLLINS, Colo., Oct. 7 /- A...examining embryonic stem cell self-renewal,report...lastim (recombinant,human serum albumin) was an ef...cell culture., The article entitled, "The ground ...sed that researchers used Cellastim as a recombina...
(Date:10/7/2008)... CAMBRIDGE, Mass., Oct. 7 /- Tali... data on several of the Company,s pipeline,candida...ement Workshop in,Basel, Switzerland. The data hig...l models of complement-mediated diseases., "These...vitro studies,presented at the conference, reveal ...
(Date:10/7/2008)... Several abstracts highlighting CIMZIA,s long-...n,s disease patients presented at American College.../- Data from two studies,pr...f Gastroenterology,(ACG) Annual Meeting demonstrat...EGylated anti-TNF alpha (Tumor Necrosis Factor alp...
(Date:10/7/2008)... SAN DIEGO, Oct. 7 /- A...today that a poster entitled "RDEA119, a Potent,an...in Dextran Sulfate,Sodium (DSS) -- induced Chronic...ollege of Gastroenterology (ACG) 2008 Annual Meeti... data from a preclinical study of,RDEA119, the Com...
Breaking Medicine Technology:In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4The story of Max Perutz a pioneering biologist with a remarkable passion for life 2832 1Nominations for Outstanding Cancer Survivor Award Being Accepted by Karmanos Cancer Institute Through April 27 16388 1Nominations for Outstanding Cancer Survivor Award Being Accepted by Karmanos Cancer Institute Through April 27 16388 2Obesity Costs U S Companies as Much as 2445 Billion a Year The Conference Board Reports 16384 1Obesity Costs U S Companies as Much as 2445 Billion a Year The Conference Board Reports 16384 2Obesity Costs U S Companies as Much as 2445 Billion a Year The Conference Board Reports 16384 3ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 1ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 2ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 3ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 4ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 5ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 6ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 7...Shock Protein 90 Inhibitor,Reveal Further Evidence..., CAMBRIDGE, Mass. and GAITHERSBURG, Md., June 5, ... Inc. (Nasdaq:INFI) and,MedImmune, Inc. (Nasdaq:ME... Phase I clinical trial of the companies, heat sho...nts with relapsed,refractory gastrointestinal str...
...Newswire-FirstCall/ --,Alexza Pharmaceuticals, Inc... Annual NCDEU Meeting the results of a Phase I cli...s being developed for,the treatment of acute agita...DEU meeting is co-sponsored by the National Instit...linical,Psychopharmacology. , The poster presentat...
Other Medicine Technology:Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 2Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 3Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 4Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 5Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 6Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 7Alexza Pharmaceuticals to Present AZ-004 (Staccato Loxapine),Clinical Data at the Annual NCDEU Meeting 2...ontinuous low-flow nebulizer performance. Patented...allows for optimal medication and Heliox delivery ...vere asthma, COPD and pneumonia in both routine an... mouth and T-piece to deliver high-output, low-flo...
... diverse medical products for more than 58 years. ...anding reputation for innovation, quality and cust...ecognized brands include the Labtron® line of ... products, Bristoline® microscopes, HealthTeam...
...contains everything the health care professional n...ickly and efficiently: 7 nebulizers, T-piece and m...yringe and needle., ,Shipped 5 kits per case., ,...ed Use: AsthmaKit is a procedural kit providing th...
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only
Medicine Products: